Bausch Health Companies Inc. (BHC) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Bausch Health fourth-quarter and full-year 2025 earnings conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions)

    大家好,歡迎參加博士倫健康公司2025年第四季及全年業績電話會議及網路直播。(操作說明)提醒各位,本次會議正在錄音。(操作說明)

  • It's now my pleasure to turn the call over to your host, Garen Sarafian, Vice President, Investor Relations. Garen, please go ahead.

    現在我很高興將電話交給主持人,投資人關係副總裁加倫·薩拉菲安。蓋倫,請繼續。

  • Garen Sarafian - Vice President, Investor Relations

    Garen Sarafian - Vice President, Investor Relations

  • Good afternoon, and welcome to Bausch Health's fourth-quarter and full-year 2025 earnings conference call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas Appio, Chief Executive Officer; JJ Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development.

    下午好,歡迎參加博士倫健康公司2025年第四季及全年業績電話會議。我是投資人關係副總裁加倫‧薩拉菲安。今天參加電話會議的有:執行長 Thomas Appio;財務長 JJ Charhon;以及首席醫療官兼研發主管 Jonathan Sadeh。

  • Before we begin, I would like to remind you that today's presentation contains forward-looking information. Please take a moment to review the forward-looking statements disclaimer at the beginning of the slides accompanying this presentation as it contains important information.

    在開始之前,我想提醒各位,今天的演講內容包含前瞻性資訊。請花點時間閱讀本簡報幻燈片開頭的“前瞻性聲明免責聲明”,因為它包含重要資訊。

  • Actual results may differ materially from those expressed or implied in these forward-looking statements, and you should not place undue reliance on them. Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations.

    實際結果可能與這些前瞻性聲明中明示或暗示的結果有重大差異,您不應過度依賴這些聲明。另請參閱我們向美國證券交易委員會提交的文件以及向加拿大證券監管機構提交的文件,其中討論了可能導致實際結果與預期結果有重大差異的某些風險因素。

  • We use non-GAAP financial measures to help investors better understand our operating performance. These non-GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to and not as a substitute for measures calculated in accordance with GAAP. Reconciliations to our non-GAAP measures are included in the appendix of the slides accompanying this presentation, which are available on Bausch Health's Investor Relations website.

    我們使用非GAAP財務指標來幫助投資者更了解我們的經營績效。這些非GAAP指標可能與其他公司使用的類似名稱的指標不具可比性,應作為GAAP指標的補充,而非替代指標。本簡報的附錄中包含了與我們非GAAP指標的調節表,這些投影片可在博士倫健康投資者關係網站上找到。

  • Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Wednesday, February 18, will focus on Bausch Health, excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced this morning. We will refer to year-over-year comparisons with the same period last year, unless otherwise noted.

    最後,本簡報中的財務指導僅截至今日有效。我們不承擔更新指南的任何義務。我們今天(2 月 18 日,星期三)的討論將集中在博士倫健康(Bausch Health)上,但不包括博士倫公司(Bausch + Lomb)。不過,我們將簡要地評論一下博士倫今天上午公佈的業績。除非另有說明,否則我們將採用與去年同期相比的同比數據。

  • With that, I will turn the call over to our CEO, Tom Appio.

    接下來,我將把電話交給我們的執行長湯姆·阿皮奧。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thank you, Garen, and welcome to everyone joining our earnings call today. Our year concluded with an impressive 11th consecutive quarter of growth in both revenue and adjusted EBITDA, reflecting our organization's consistent performance. This success is powered by our global team's unwavering commercial focus and operational excellence as full-year results exceeded our guidance on all key metrics.

    謝謝蓋倫,也歡迎各位參加我們今天的財報電話會議。我們全年實現了令人矚目的連續第 11 個季度營收和調整後 EBITDA 成長,這反映了我們公司一貫的良好業績。這項成功得益於我們全球團隊堅定不移的商業專注和卓越的營運能力,全年業績在所有關鍵指標上都超過了我們的預期。

  • The fourth quarter gave us an opportunity to reflect on the progress we have made over the past year. Our commercial performance has remained strong across the markets we serve. Our capital structure has improved significantly. Our operating model has continued to deliver efficiencies, all of which has given us the ability to proactively pursue business development to enhance our long-term outlook.

    第四季讓我們有機會反思過去一年所取得的進展。我們在所服務的各個市場都維持了強勁的商業表現。我們的資本結構已顯著改善。我們的營運模式持續提高效率,使我們能夠積極主動地追求業務發展,從而增強我們的長期前景。

  • As we begin 2026, our strategic priorities remain firm and our approach consistent. We continue to prioritize initiatives that yield the highest value across our organization. Our global footprint and 2025 performance give us confidence for future growth.

    進入2026年,我們的戰略重點依然堅定,我們的方法也始終如一。我們將繼續優先考慮那些能為整個組織帶來最大價值的措施。我們的全球佈局和 2025 年業績預期讓我們對未來的成長充滿信心。

  • While JJ will walk through the financials in more detail, I would like to take a few minutes to highlight our fourth-quarter performance.

    雖然 JJ 會更詳細地介紹財務數據,但我想花幾分鐘時間重點介紹我們第四季的業績。

  • In the fourth quarter, Bausch Health, excluding Bausch + Lomb, increased revenue by 9% on a reported basis and 5% on an organic basis when compared to the fourth quarter of 2024. Salix, in particular, demonstrated resilient demand, excluding Medicaid, supported by solid volume in remaining channels and continued execution across promotional, access, and digital capabilities.

    第四季度,除博士倫外,博士倫健康業務的收入按報告基準計算增長了 9%,按有機增長基準計算增長了 5%(與 2024 年第四季度相比)。特別是 Salix,在 Medicaid 除外的情況下,展現出了強勁的需求,這得益於其他渠道的穩健銷量以及在促銷、渠道拓展和數位化能力方面的持續執行。

  • Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, increased by approximately 9% compared to the prior-year period and ahead of implied guidance for the quarter. The business continued to operate efficiently as teams manage spending thoughtfully while sustaining the investment needed to support growth.

    除博士倫外,博士倫健康調整後的 EBITDA 比上年同期成長約 9%,高於本季的預期。公司在團隊謹慎管理支出的同時,維持了支持成長所需的投資,從而維持了高效的營運。

  • On December 1, 2025, we acquired Shibo, full-service aesthetics distribution platform in China, strengthening our direct commercial presence in this key market. This strategic transaction provides us with the access to one of the largest global aesthetics markets and enhances our ability to serve providers directly.

    2025年12月1日,我們收購了中國全方位美容產品分銷平台世博,加強了我們在這一關鍵市場的直接商業存在。這項策略性交易使我們能夠進入全球最大的醫美市場之一,並增強我們直接服務於醫療服務提供者的能力。

  • Our cash generation remained healthy, allowing us to achieve another year of over $1 billion in adjusted operating cash flow while also reducing our net debt by several hundred million dollars. Lastly, we further improved our debt maturity profile by approximately $1.7 billion through a debt exchange in late December 2025. This transaction further strengthened our balance sheet and provided additional flexibility as we evaluate opportunities to unlock value across the portfolio.

    我們的現金流保持健康,使我們連續第二年實現了超過 10 億美元的調整後經營現金流,同時也減少了數億美元的淨債務。最後,我們在 2025 年 12 月下旬透過債務交換,進一步改善了我們的債務到期結構,減少了約 17 億美元。此交易進一步增強了我們的資產負債表,並為我們評估釋放投資組合價值的機會提供了更大的靈活性。

  • For the full year, Bausch Health, excluding Bausch + Lomb, delivered year-over-year growth of 7% on a reported basis and 6% on an organic basis. This reflects broad-based performance across the enterprise.

    全年來看,不包括博士倫在內的博士健康業務,按報告數據計算年增 7%,以有機成長計算年增 6%。這反映了企業整體的整體績效表現。

  • We achieved double-digit adjusted EBITDA growth, excluding Bausch + Lomb, for full-year 2025, ahead of expectations. Excluding the third-quarter charge related to acquired in-process research and development would yield an even higher adjusted EBITDA growth rate for the year.

    2025 年全年,我們實現了兩位數的調整後 EBITDA 成長(不包括博士倫),超乎預期。如果排除與收購的在研項目相關的第三季費用,則全年的調整後 EBITDA 成長率會更高。

  • Salix and Solta delivered double-digit top line growth of 11% and 18%, respectively. Three of our four segments grew revenue this year and three improved profitability, highlighting the diversification of the portfolio and the contributions generated from multiple areas of the business.

    Salix 和 Solta 的營收分別實現了兩位數的成長,增幅分別為 11% 和 18%。今年,我們四個業務部門中有三個實現了收入成長,三個實現了盈利能力提升,這凸顯了業務組合的多元化以及多個業務領域所做出的貢獻。

  • At the product level, performance during the year remained healthy across multiple important areas. Xifaxan revenue grew 11% for the year, reflecting the continued impact of our commercial team's efforts. Thermage revenue grew a robust 19%, anchored in Asia Pacific. And other products such as Ryaltris and CABTREO also grew very well. These outcomes reflect consistent demand, strong field activity, and targeted investments throughout the year. Overall, 2025 represented another year of excellent execution, leading to results above guidance.

    從產品層面來看,本年度在多個重要領域均維持了良好的績效表現。Xifaxan 的營收全年成長了 11%,反映了我們商業團隊持續努力的影響。Thermage 的營收實現了強勁成長 19%,主要得益於亞太地區的成長。Ryaltris 和 CABTREO 等其他產品也發展得非常好。這些成果反映了全年持續的需求、強勁的市場活動和有針對性的投資。整體而言,2025 年又是執行力出色的一年,業績超乎預期。

  • Let me take a moment to provide a brief update on RED-C. We are disappointed by the outcome we announced in January that, while safe and well tolerated, neither Phase 3 trial met its primary endpoint. We are currently reviewing the full data set to determine potential new development opportunities.

    讓我花點時間簡單介紹一下 RED-C 的最新情況。我們對1月宣布的結果感到失望,儘管安全性和耐受性良好,但兩項3期試驗均未達主要終點。我們目前正在審查全部資料集,以確定潛在的新發展機會。

  • Reflecting on the overall performance, we closed 2025 with strong results. Our team advanced our strategic priorities, strengthened the company's operational position and executed with excellence. I appreciate the unwavering commitment our teams worldwide have shown over the course of the year. Together, we remain focused and committed to delivering results for shareholders.

    回顧整體表現,我們以優異的成績結束了 2025 年。我們的團隊推進了策略重點,加強了公司的營運地位,並出色地完成了任務。我非常感謝我們全球團隊在過去一年中展現出的堅定不移的奉獻精神。我們將繼續齊心協力,專注於為股東創造回報。

  • I will now hand it over to JJ to walk you through the detailed financial results. JJ?

    現在我將把講解工作交給JJ,讓他為大家詳細介紹財務結果。JJ?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Thank you, Tom. Let's start with our consolidated non-GAAP financial performance for the fourth quarter, which you will find on page 11. Revenue was $2.796 billion, up 9% on a reported basis compared to the same quarter a year ago. Adjusted gross margin was 71.6%, which was 80 basis points lower than the same period a year ago. Adjusted operating expenses were $1.033 billion, an increase of $75 million year over year.

    謝謝你,湯姆。讓我們先來看看我們第四季的綜合非GAAP財務業績,您可以在第11頁找到它。營收為 27.96 億美元,以報告數據計算,比去年同期成長 9%。調整後毛利率為 71.6%,比去年同期下降了 80 個基點。經調整後的營運費用為 10.33 億美元,比上年增加 7,500 萬美元。

  • Adjusted R&D expenses were $161 million, which was a $2 million decrease when compared to the fourth quarter of 2024. Adjusted EBITDA was $1.052 billion in the fourth quarter, an increase of 13% year over year. Finally, adjusted operating cash flow was $515 million.

    經調整後的研發費用為 1.61 億美元,比 2024 年第四季減少了 200 萬美元。第四季調整後 EBITDA 為 10.52 億美元,較去年同期成長 13%。最後,調整後的營運現金流為 5.15 億美元。

  • Moving now to the fourth quarter of Bausch Health performance, excluding Bausch + Lomb, starting on page 15. As Tom indicated, we had another strong operational performance across all metrics in Q4.

    現在進入博士倫公司(不包括博士健康)第四季業績,從第 15 頁開始。正如湯姆所指出的那樣,我們在第四季度所有指標上都取得了強勁的營運表現。

  • Revenue for the fourth quarter was $1.391 billion, up 9% on a reported basis. Adjusted EBITDA for the fourth quarter was $773 million, a 9% increase from the fourth quarter of 2024. Adjusted operating cash flow for the fourth quarter was $362 million, down $205 million year over year, primarily due to the change in timing of our cash interest payments following the refinancing we executed on April 8, 2025. Our strong cash flow generation in Q4 allowed us to reduce our net debt by approximately $320 million, which was much better than originally anticipated.

    第四季營收為 13.91 億美元,按報告數據計算成長 9%。第四季調整後 EBITDA 為 7.73 億美元,比 2024 年第四季成長 9%。第四季調整後的營運現金流為 3.62 億美元,年減 2.05 億美元,主要原因是我們在 2025 年 4 月 8 日執行再融資後,現金利息支付的時間發生了變化。第四季強勁的現金流使我們能夠減少約 3.2 億美元的淨債務,這比最初預期的要好得多。

  • Turning now to our fourth-quarter performance by segment, starting with Salix on page 17. Salix revenues in the fourth quarter were $693 million, which was an impressive 9% increase year over year on a reported basis. This strong performance in Q4 was ahead of expectations. While we had anticipated the continuation of our double-digit script growth across all existing channels, we also benefited from some higher-than-planned residual volume from several state Medicaid customers. We do not expect this to be a material revenue driver moving forward.

    現在來看看我們第四季各業務部門的業績,首先是第 17 頁的 Salix。Salix 在第四季營收為 6.93 億美元,以報告數據計算,年增 9%,增幅令人矚目。第四季強勁的業績超出了預期。雖然我們預計所有現有管道的處方量將繼續保持兩位數成長,但我們也受益於幾個州醫療補助客戶的剩餘量高於計劃。我們預計這不會成為未來重要的收入驅動因素。

  • Now moving to the International segment, which you will find on page 18. Revenues were $306 million, an increase of 10% on a reported basis and 2% on an organic basis compared to the same period a year ago. While the performance was strong overall, the results by geography was mixed. EMEA and LatAm grew double digit on a reported basis, while Canada contracted 6%.

    現在進入國際版塊,您可以在第 18 頁找到它。營收為 3.06 億美元,按報告數據計算成長 10%,以有機成長計算成長 2%,與去年同期相比。雖然整體表現強勁,但不同地區的成績卻參差不齊。歐洲、中東和非洲地區以及拉丁美洲地區按報告數據實現了兩位數成長,而加拿大則萎縮了 6%。

  • Congratulations to the EMEA team for achieving its 12th consecutive quarter of organic revenue growth, which is very impressive. Also worth noting is our performance in LatAm, which returned to growth with a 22% increase in revenue on a reported basis and still 11% on an organic basis. What's more, growth was balanced across most of our core brands this quarter.

    恭喜 EMEA 團隊連續第 12 個季度實現有機收入成長,這非常令人印象深刻。值得注意的是,我們在拉丁美洲的業績也恢復了成長,按報告數據計算,收入增長了 22%,以有機增長計算,收入仍增長了 11%。此外,本季我們大多數核心品牌都實現了均衡成長。

  • Finally, Canada's revenue contraction was due to a reduction in Wellbutrin volume, which faced more generic competition in this quarter compared to the same quarter one year ago. This was partially offset by the double-digit growth of our promoted products portfolio led by CABTREO and Ryaltris.

    最後,加拿大收入的下降是由於安非他酮(Wellbutrin)銷量減少,與去年同期相比,該藥在本季面臨更激烈的仿製藥競爭。部分抵消了這一影響的是,以 CABTREO 和 Ryaltris 為首的推廣產品組合實現了兩位數的成長。

  • Now let's review the performance of our Solta Medical segment, which you will find on page 19. Revenues were $137 million, a slight decrease of 1% on a reported basis and flat on an organic basis compared to the same period last year. Solta's solid operational performance was negatively impacted by the transition of our full-service distributor in China. Excluding this onetime impact, we estimate that Solta revenues would have been up mid-single digits in the fourth quarter.

    現在讓我們回顧一下 Solta Medical 業務板塊的業績,詳情請見第 19 頁。營收為 1.37 億美元,按報告數據計算略微下降 1%,以有機成長計算與去年同期持平。Solta 穩健的營運表現受到了中國全方位服務經銷商過渡的負面影響。排除這一一次性影響,我們估計 Solta 第四季的營收將實現個位數中段的成長。

  • Separately, special mention goes to our team in South Korea, which continues to perform exceptionally well. Reported revenue in that market was up 40% this quarter, making South Korea our largest revenue-generating geography for Solta in 2025.

    另外,特別要提及我們在韓國的團隊,他們繼續表現出色。該市場本季報告營收成長了 40%,使韓國成為 Solta 在 2025 年最大的收入來源。

  • Turning now our focus to the quarterly performance of our Diversified segment, which you will find on page 20. Revenues were $255 million, an increase of 12% on a reported basis, mostly due to the improved net pricing in the quarter.

    現在,我們將重點放在多元化業務部門的季度業績,詳情請見第 20 頁。營收為 2.55 億美元,按報告數據計算成長 12%,主要原因是本季淨定價有所改善。

  • Finally, let me wrap up the segment discussion for the fourth quarter by commenting briefly on Bausch + Lomb results, which you will find on page 21. Revenues were $1.405 billion, up 10% on a reported basis compared to the same period last year. B&L's strong revenue performance in Q4 was led by its pharmaceuticals business, which had an impressive 16% growth year over year on a reported basis, while its other two businesses, Vision Care and Surgical, each grew 8%.

    最後,讓我簡單評論一下博士倫的業績,以此來結束第四季度的討論,您可以在第 21 頁找到相關結果。營收為 14.05 億美元,以報告數據計算,比去年同期成長 10%。B&L 第四季度強勁的收入表現主要得益於其製藥業務,該業務按報告數據同比增長了 16%,而其另外兩項業務——視力保健和外科手術——均增長了 8%。

  • Now let's end the review of the fourth quarter by highlighting improvements we have made to our capital structure. There were three major highlights for the quarter. First, we repaid our $300 million accounts receivable facility and in the process, lowered our average cost of debt. We also completed a $1.7 billion secured debt exchange, which allowed us to push out maturities for four years and capture $80 million of debt discounts. Finally, we generated $362 million of adjusted operating cash flow and reduced our net debt by more than $300 million quarter over quarter. The strengthening of our balance sheet caps a great quarter performance across all metrics.

    現在讓我們透過重點介紹我們在資本結構方面所做的改進來結束第四季度的回顧。本季有三大亮點。首先,我們償還了 3 億美元的應收帳款,並在此過程中降低了我們的平均債務成本。我們還完成了 17 億美元的擔保債務交換,這使我們能夠將到期日推遲四年,並獲得 8000 萬美元的債務折扣。最後,我們實現了 3.62 億美元的調整後營運現金流,淨債務較上季減少了 3 億美元以上。資產負債表的增強,為本季各項指標的優異表現錦上添花。

  • Now before I cover our guidance for 2026, let me provide a quick wrap-up of our outstanding full-year performance and the progress we've made in the last 12 months. We grew revenue 7% and adjusted EBITDA 10%, demonstrating our continued commitment to driving profitable growth and increasing operating leverage.

    在介紹我們對 2026 年的展望之前,讓我快速總結一下我們出色的全年業績以及我們在過去 12 個月中取得的進展。我們實現了7%的收入成長和10%的調整後EBITDA成長,這表明我們持續致力於推動獲利成長和提高營運槓桿。

  • While we recognize that some of 2025 growth was a result of nonrecurring drivers, the underlying operating growth would still be high-single digit year over year. More importantly, it is worth acknowledging that all these outstanding operational results came without the benefit of any major acquisitions and solely through the optimization of the same portfolio we've had for the last four years.

    雖然我們認識到 2025 年的部分成長是由非經常性因素造成的,但基本的營運成長仍將實現高個位數年成長。更重要的是,值得肯定的是,所有這些出色的營運成果都是在沒有進行任何重大收購的情況下取得的,而僅僅是透過優化我們過去四年一直擁有的投資組合來實現的。

  • Finally, we significantly improved our debt maturity profile by executing two large refinancing transactions, totaling together $9.6 billion and leaving now less than $700 million of maturities obligation until the end of 2027. This is an incredible turnaround when thinking about where we stood just 12 months ago. That being said, a lot more work lies ahead, but our view is that 2025 mark an inflection point in our operational and financial trajectory.

    最後,我們透過執行兩項總額達 96 億美元的大型再融資交易,大幅改善了債務到期結構,目前到 2027 年底到期的債務不足 7 億美元。考慮到我們12個月前的處境,這真是一個令人難以置信的轉變。儘管如此,未來還有很多工作要做,但我們認為 2025 年將是我們營運和財務軌蹟的轉捩點。

  • Now let me provide you with our 2026 financial guidance for Bausch Health, excluding Bausch + Lomb, which you will find on page 25. For 2026, we expect revenues to be between $5.25 billion and $5.4 billion. The midpoint of that range would translate into a 3% increase year over year. Adjusted EBITDA is expected to be between $2.875 billion and $2.950 billion, representing a 4% increase year over year at the midpoint. Finally, we expect adjusted operating cash flow to be between $1.2 billion and $1.275 billion. The midpoint of that range would translate to a 4% increase year over year. Please note that the guidance for 2026 is at current FX rates.

    現在讓我向您提供 Bausch Health 的 2026 年財務指導,但不包括 Bausch + Lomb,您可以在第 25 頁找到相關資訊。我們預計 2026 年的營收將在 52.5 億至 54 億美元之間。該範圍的中點相當於年增 3%。調整後 EBITDA 預計在 28.75 億美元至 29.5 億美元之間,以中間值計算,年增 4%。最後,我們預計調整後的營運現金流將在 12 億美元至 12.75 億美元之間。該範圍的中點相當於年增 4%。請注意,2026 年的預測是基於當前匯率計算的。

  • Let me also add that from a phasing perspective, we anticipate a stronger growth rate in the first half of 2026, given the temporary nature of some of the benefits we recorded in the second half of 2025. With that context, and before I hand it over to Tom, let me review our key financial priorities and how they will be pursued in the coming year.

    我還想補充一點,從階段性角度來看,考慮到我們在 2025 年下半年取得的一些成果具有暫時性,我們預計 2026 年上半年的成長率會更高。鑑於以上背景,在將發言權交給湯姆之前,讓我回顧一下我們的主要財務優先事項以及來年我們將如何實現這些優先事項。

  • First, increasing the value of Bausch Health operational assets through innovation, optimizing the growth of our portfolio of brands across the globe as well as pursuing opportunities to further expand our portfolio of assets through business development. There is no major change versus what we set out last year, making 2026 an extension of what we accomplished in 2025.

    首先,透過創新提升博士倫健康營運資產的價值,優化我們在全球範圍內的品牌組合成長,並透過業務發展尋求進一步擴大我們資產組合的機會。與我們去年制定的計劃相比,沒有重大變化,2026 年是我們在 2025 年所取得成就的延續。

  • Second, evaluating all options for unlocking value for all stakeholders, including maximizing the value of our Bausch Health and Bausch + Lomb assets. Our improved debt maturity profile now gives us the ability to use value maximization for shareholders as our primary guide for future asset monetization decisions.

    其次,評估所有能為所有利害關係人創造價值的方案,包括最大限度地發揮我們博士倫健康公司和博士倫資產的價值。我們現在改善了債務到期結構,使我們能夠以股東價值最大化為主要指導原則,制定未來的資產貨幣化決策。

  • And third, continue to optimize our capital structure. Now that we have completed the largest refinancing transaction in our history, the approach will be more opportunistic while maintaining maximum flexibility for funding any future investment in Bausch Health.

    第三,繼續優化我們的資本結構。現在我們已經完成了公司歷史上最大的再融資交易,我們將採取更具機會主義的做法,同時保持最大的靈活性,為未來對博士倫健康的任何投資提供資金。

  • In short, we expect 2026 to be another opportunity to make good progress against some of our key finance priorities with a more balanced approach between tactical improvement and strategic value creation.

    簡而言之,我們預計 2026 年將是我們在實現一些關鍵財務優先事項方面取得良好進展的另一個機會,屆時我們將採取更加平衡的戰術改進和戰略價值創造相結合的方式。

  • I will now turn it over to Tom.

    現在我把任務交給湯姆。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thank you, JJ. I would like to now shift from the financials to how we are positioning the company for success in 2026. I would like to highlight a few of our segments and businesses today to illustrate the breadth of our underlying portfolio and the many opportunities we see ahead.

    謝謝你,JJ。現在我想從財務方面轉向我們如何為公司在 2026 年取得成功做好準備。今天,我想重點介紹我們的一些業務板塊和業務,以說明我們基礎投資組合的廣度以及我們看到的未來​​眾多機會。

  • Salix is an industry leader in gastroenterology and hepatology. For over 35 years, we have built our company position by establishing long-standing relationships with health care providers, institutions and patients. Xifaxan, Relistor and Trulance are trusted set of brands that anchor our leadership position. Our focus on education, on patient access and ongoing physician engagement reinforces our standing as one of the top GI pharmaceutical companies in the United States.

    Salix是胃腸病學和肝病學領域的行業領導者。35 年來,我們透過與醫療保健提供者、機構和患者建立長期合作關係,鞏固了公司的地位。Xifaxan、Relistor 和 Trulance 是一系列值得信賴的品牌,鞏固了我們的領導地位。我們專注於教育、病患就醫途徑和與醫生的持續互動,這鞏固了我們作為美國頂尖胃腸道製藥公司之一的地位。

  • In 2026, we will continue our momentum with Salix in commercial and Medicare segments. We continue to leverage our customer insights platform to find new patient starts and accelerate starting treatment in all GI conditions that we treat, including OHE, IBS-D, IBS-C and OIC. Using AI enables us to do this in a way that is faster, is smarter and is more efficient.

    2026年,我們將繼續保持與Salix在商業和醫療保險領域的合作動能。我們繼續利用客戶洞察平台尋找新的患者,並加速治療所有胃腸道疾病(包括 OHE、IBS-D、IBS-C 和 OIC)的治療。利用人工智慧,我們可以更快、更聰明、更有效率地完成這項工作。

  • In 2026, we will leverage our data-driven approach to reach patients through direct-to-consumer advertising and to reach health care providers through improved targeting. This is a franchise we expect will continue to perform.

    2026 年,我們將利用數據驅動的方法,透過直接面向消費者的廣告來接觸患者,並透過改進的定向投放來接觸醫療保健提供者。我們預計該系列產品將繼續保持良好業績。

  • Innovation remains central to the Salix segment. Larsucosterol, our Phase 3 program for alcohol-associated hepatitis, or AH, represents an important potential advancement. AH remains an area of substantial unmet need, and we are committed to advancing this program to deliver meaningful therapeutic options for patients. Following quarter end, we began enrolling patients in the Phase 3 study, marking a key step forward for this program.

    創新仍然是Salix業務的核心。Larsucosterol 是我們針對酒精相關性肝炎(AH)的 3 期臨床試驗項目,代表著一項重要的潛在進展。AH 仍然是一個存在巨大未滿足需求的領域,我們致力於推進該項目,為患者提供有意義的治療選擇。季度末之後,我們開始招募患者參與 3 期研究,這標誌著該計畫向前邁出了關鍵一步。

  • Turning to Solta. Solta is a leading medical aesthetics platform and offers a comprehensive set of energy-based devices within the global aesthetics market. Our technologies address a broad range of clinical applications, enabling us to serve diverse provider segments and consumer needs while strengthening our competitive position across key markets.

    轉向索爾塔。Solta 是領先的醫療美容平台,在全球美容市場提供全套基於能量的設備。我們的技術可滿足廣泛的臨床應用需求,使我們能夠服務不同的醫療服務提供者群體和消費者需求,同時增強我們在關鍵市場的競爭地位。

  • Solta's above-market performance reflects a long history of product innovation and strong commercial platform. We continue to invest thoughtfully to drive long-term growth and capture the significant opportunities ahead by: investing in our people, strengthening our management structure, developing our team members and attracting top talent to support the next phase of growth, investing in scale.

    Solta 的業績優於市場平均水平,反映了其長期以來在產品創新和強大商業平台方面的努力。我們將繼續深思熟慮地進行投資,以推動長期成長並抓住未來的重要機遇,具體措施包括:投資於我們的員工、加強我們的管理結構、培養我們的團隊成員、吸引頂尖人才以支持下一階段的成長、投資於規模化。

  • As mentioned earlier, we completed the acquisition of Shibo's aesthetics business in December, bringing distribution, sales and marketing capabilities fully in-house for Solta China. This enhances our reach, deepens provider and consumer engagement and increases utilization.

    如前所述,我們在 12 月完成了對 Shibo 美容業務的收購,使 Solta China 的分銷、銷售和行銷能力完全掌握在自己手中。這擴大了我們的覆蓋範圍,加深了供應商和消費者之間的互動,並提高了利用率。

  • We expect China to reclaim the number one geography for Solta in 2026. Investing in innovation, expanding our R&D organization and building new medical and clinical affairs capabilities to accelerate product development and generate robust clinical evidence. Investing in manufacturing capacity, ensuring we can meet rising global demand while maintaining quality and operational excellence. Based on the momentum we have seen to date and the opportunities we anticipate in this market, we believe that Solta is well positioned to continue delivering double-digit growth in 2026, supported by strong fundamentals.

    我們預計中國將在 2026 年重新奪回 Solta 的頭號市場地位。投資創新,擴大研發組織,建立新的醫療和臨床事務能力,以加速產品開發並產生可靠的臨床證據。投資製造能力,確保我們能夠在滿足不斷增長的全球需求的同時,保持品質和卓越的營運水平。根據我們迄今為止所看到的勢頭以及我們對該市場機會的預期,我們相信,在強勁的基本面支撐下,Solta 已做好充分準備,將在 2026 年繼續實現兩位數的增長。

  • Let me now turn to our International segment, which is often underappreciated yet continues to perform well, and we expect will remain an important contributor to the company in 2026. The segment includes several diverse markets, each with a robust commercial model and well-established brands.

    現在讓我來談談我們的國際業務部門,該部門經常被低估,但一直表現良好,我們預計到 2026 年仍將是公司的重要貢獻者。該細分市場包含多個不同的市場,每個市場都有強大的商業模式和成熟的品牌。

  • Within our EMEA market, we expect Central Europe to maintain its solid position, supported by established presence in Poland with an excellent team. This presence will allow us to introduce new products and product line extension. We plan to continue leveraging our position as the number one pharmaceutical company in Serbia across multiple therapeutic areas.

    在我們的 EMEA 市場中,我們預計中歐將保持其穩固的地位,這得益於我們在波蘭建立的穩固業務和優秀的團隊。此次入駐將使我們能夠推出新產品並擴展產品線。我們計劃繼續發揮我們在塞爾維亞多個治療領域中作為排名第一的製藥公司的地位。

  • In Mexico, the largest component of our Latin American business, we are ranked as the number two dermatology company. In both Mexico and Colombia, our BEDOYECTA products are ranked as the number one complex B brand. Across Mexico and Central America, our Bausch Health branded generics hold at least one top three position across the therapeutic categories. We have now entered the cardiometabolic market in Latin America, which represents a large and growing opportunity for Bausch Health.

    在墨西哥——我們拉丁美洲業務的最大組成部分——我們位列皮膚科公司第二名。在墨西哥和哥倫比亞,我們的 BEDOYECTA 產品都被評為排名第一的複合維生素 B 品牌。在墨西哥和中美洲,我們的博士倫健康品牌仿製藥在各個治療類別中至少佔據前三名中的一個位置。我們現在已經進入拉丁美洲的心血管代謝市場,這對博士倫健康來說是一個巨大且不斷增長的機會。

  • Our infrastructure, brand recognition and commercial reach position us well to compete effectively in the cardiometabolic category. We expect Mexico to continue to return to growth in 2026, including drivers BEDOYECTA and our newly launched cardiometabolic franchise.

    我們的基礎設施、品牌知名度和商業覆蓋範圍使我們在心血管代謝領域擁有強大的競爭力。我們預計墨西哥將在 2026 年繼續恢復成長,包括 BEDOYECTA 驅動因素和我們新推出的心血管代謝特許經營權。

  • In Canada, we are ranked as the number one dermatology company supported by strong brands, including CABTREO and JUBLIA that continue to perform well and solidify our presence in the market. Together with our promoted products, we expect promoted products to continue to grow in double digits in 2026.

    在加拿大,我們憑藉 CABTREO 和 JUBLIA 等強大品牌,成為排名第一的皮膚病學公司,這些品牌持續表現良好,鞏固了我們在市場上的地位。加上我們推廣的產品,我們預計推廣產品在 2026 年將持續保持兩位數的成長。

  • With the results we have seen and the opportunities across our global footprint, we expect our International segment to deliver growth in 2026, supported by durable underlying fundamentals.

    憑藉我們已取得的成果以及我們在全球範圍內所面臨的機遇,我們預計在穩健的基本面支撐下,我們的國際業務部門將在 2026 年實現成長。

  • Our five strategic pillars will continue to guide Bausch Health in 2026. These pillars: people, growth, innovation, efficiency, and unlocking value provide structure and clarity to our decision-making. They drive alignment of our teams on the actions required to deliver sustainable results. These priorities shape our daily operations, reinforcing accountability, ownership, execution and a focus on progress.

    2026年,我們的五大戰略支柱將繼續指導博士倫健康的發展。人員、成長、創新、效率和價值釋放這三大支柱為我們的決策提供了結構和清晰度。他們推動我們的團隊在實現可持續成果所需的行動上達成一致。這些優先事項塑造了我們的日常運營,強化了問責制、主人翁意識、執行力和對進步的關注。

  • We remain committed to commercial, operational, and R&D excellence, along with the proactive pursuit of business development initiatives that expand our portfolio and enhance our long-term outlook. We finished 2025 on a high note with exceptional full-year results, reflecting significant progress across our strategic priorities.

    我們將繼續致力於商業、營運和研發方面的卓越表現,並積極尋求業務發展舉措,以擴大我們的產品組合併增強我們的長期前景。2025 年我們取得了優異的全年業績,完美收官,這反映出我們在各項策略重點方面取得了顯著進展。

  • I want to extend my sincere gratitude to the Bausch Health team worldwide. These achievements are a direct result of your passion, intelligence, and unwavering dedication. We are entering 2026 with confidence the company has a strong team and a diversified portfolio with multiple paths to growth and innovation.

    我謹向博士倫健康全球團隊表達我最誠摯的謝意。這些成就直接源自於你的熱情、智慧和堅定不移的奉獻。我們滿懷信心地邁入 2026 年,公司擁有強大的團隊和多元化的產品組合,為成長和創新提供了多種途徑。

  • With that, we can open the line for Q&A.

    這樣,我們就可以開始問答環節了。

  • Operator

    Operator

  • (Operator Instructions) Umer Raffat, Evercore ISI.

    (操作說明)Umer Raffat,Evercore ISI。

  • Unidentified Participant

    Unidentified Participant

  • This is [JP] in for Umer. Congrats on the quarter. I have one question. Post RED-C readout, what is your updated decision framework for the separation? How are you thinking about gating items and debt repayments? What's -- can you please illustrate?

    這是[JP]代替Umer。恭喜你本季取得佳績。我有一個問題。RED-C 偵測結果出來後,你們對分離的決策架構有何更新?您打算如何限制物品交易和債務償還?什麼?能解釋一下嗎?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah. Thanks for the question. I think that the way I would say it is there's no change. We're -- of course, we're disappointed in the results from RED-C. But we continue to focus on repaying debt and reinvesting in our business, whether promoting existing products, developing new products or engaging, as I said in my prepared remarks, engaging in business development activities, which is one of the things we are accelerating now that we have significantly changed our capital structure with the refinancing.

    是的。謝謝你的提問。我認為,我的說法是,沒有任何變化。我們當然對 RED-C 的結果感到失望。但我們將繼續專注於償還債務和再投資於我們的業務,無論是推廣現有產品、開發新產品,還是像我在準備好的演講稿中提到的那樣,開展業務拓展活動。鑑於我們透過再融資大幅改變了資本結構,業務拓展活動正是我們正在加速推進的事情之一。

  • Unidentified Participant

    Unidentified Participant

  • Following up on the BD --

    BD後續報道——

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah. Sure.

    是的。當然。

  • Unidentified Participant

    Unidentified Participant

  • Yeah. Can you please give some more color about your business development plans?

    是的。能否詳細介紹一下您的業務發展計畫?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Sure. Well, firstly, as you know, the acquisition of DURECT -- and Jonathan is here, and he can talk about that. And when we acquired DURECT, we acquired it not just for alcohol-associated hepatitis, but also as a platform. So we have been -- and Jonathan can speak to that.

    當然。首先,正如您所知,我們收購了 DURECT——喬納森就在這裡,他可以談談這件事。我們收購 DURECT 的目的,不僅是為了治療酒精相關性肝炎,更是為了將其視為一個平台。所以,我們一直都是這樣──喬納森可以就此作證。

  • The other thing also from business development is looking at the therapeutic areas that we compete in. We have screened a lot of assets, looking at where we can bring in acquisitions that we can leverage with our outstanding commercial team. That's one of the greatest assets of this company is the commercial excellence, both from a selling and marketing perspective. So we're looking for different assets that we can put and slot into those teams.

    業務發展方面還有一點要關注,那就是我們所處的治療領域。我們篩選了很多資產,尋找我們可以利用我們優秀的商業團隊進行收購的目標。這家公司最大的優勢之一就是其卓越的商業能力,無論是在銷售還是行銷方面。因此,我們正在尋找可以融入這些團隊的不同資源。

  • Also looking, as I talked about in my prepared remarks, on Solta, where Solta is a great brand for us. We have great innovation there, and there is opportunities to continue to look at acquisition possibilities to slot into the portfolio as well.

    正如我在準備好的演講稿中提到的,我們也在關注 Solta,Solta 對我們來說是一個很棒的品牌。我們在那裡擁有強大的創新能力,並有機會繼續尋找收購機會,將其納入投資組合。

  • I'll hand it to Jonathan, you might want to talk about the direct acquisition and why we see it as a platform.

    我把這個問題交給喬納森,你可能想談談直接收購以及我們為什麼將其視為一個平台。

  • Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

    Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

  • Yeah, of course. So Larsucosterol was really a great acquisition for us. To remind you, it's an epigenetic modulator. So prevents cell death and response to acute cell injury. DURECT did a great job of proving that this drug is very efficacious in one setting of acute cell injury and alcohol-associated hepatitis. And that's the first -- the lead indication that we have started Phase 3 with and strongly believe in the data that we saw in Phase 2.

    當然。所以,收購 Larsucosterol 對我們來說真是一筆非常棒的買賣。提醒一下,它是一種表觀遺傳調節劑。因此,它可以防止細胞死亡和對急性細胞損傷的反應。DURECT 很好地證明了這種藥物在急性細胞損傷和酒精相關性肝炎的一種情況下非常有效。這是第一個——也是我們已經開始第三階段試驗的領先指標,我們非常相信我們在第二階段試驗中看到的數據。

  • But we -- as Tom was saying, we believe this is a platform because if we do see an effect -- such a strong effect in one form of acute cell injury like alcohol-associated hepatitis. We believe and we actually DURECT has some preclinical and clinical data to suggest that in other settings of acute cell injury, we would also see efficacy. So we're now actually going over all these other potential indication and hope to prioritize some of those in the very near future.

    但是,正如湯姆所說,我們相信這是一個平台,因為如果我們真的看到效果——在酒精相關性肝炎等某種形式的急性細胞損傷中看到如此強烈的效果。我們相信,而且實際上 DURECT 也擁有一些臨床前和臨床數據,顯示在其他急性細胞損傷的情況下,我們也會看到療效。所以我們現在正在研究所有這些其他潛在的跡象,並希望在不久的將來優先考慮其中的一些跡象。

  • Operator

    Operator

  • Les Sulewski, Truist Securities.

    Les Sulewski,Truist Securities。

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • I have two and then a follow-up maybe to Jonathan. So, first on Solta, can you just share some puts and takes around the Shibo integration? Specifically, how much of the guided revenue and EBITDA growth is driven by the accounting step-up versus the volume growth of Thermage? And could you provide the expected margin accretion from the shift once the channel is fully operational?

    我有兩個問題,然後可能還會給喬納森一個後續問題。首先,關於 Solta,您能否分享一下您對 Shibo 整合的看法和看法?具體而言,預期收入和 EBITDA 成長有多少是由會計調整推動的,又有多少是由 Thermage 的銷售成長所推動的?在通路全面運作後,您能否提供一下此次調整預計帶來的利潤成長?

  • Second, on the Diversified segment, should we expect generics of Aplenzin and BRYHALI launching this year? And if so, what's a fair erosion step down to model? And how are you thinking about plugging these revenue gaps?

    其次,在多元化領域,我們是否可以預期 Aplenzin 和 BRYHALI 的仿製藥將於今年上市?如果是這樣,那麼模型中合理的侵蝕階數是多少?您打算如何彌補這些收入缺口?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Okay. Les, I'll take the first part of the question regarding Solta. So we closed the acquisition on December 1, 2025, and things are going very well with a very smooth transition. The teams in China, both from the Solta side and the Shibo side have done a wonderful job working to integrate the two companies.

    好的。萊斯,我來回答關於索爾塔的第一部分問題。因此,我們在 2025 年 12 月 1 日完成了收購,一切進展順利,過渡非常穩定。無論是索爾塔還是世博,中國團隊在整合兩家公司方面都做得非常出色。

  • I was there in the middle of December, spoke to the entire team. the Shibo team is extremely excited to be part of Solta. It has been a long-standing relationship that we've had with Shibo. So it is going very well.

    我十二月中旬去過那裡,和整個團隊都聊過。 Shibo團隊非常高興能成為Solta的一份子。我們與Shibo一直保持著長期的合作關係。一切進展順利。

  • In terms of your question regarding the accounting, I will pass that to JJ.

    關於您提出的會計方面的問題,我會轉交給 JJ 處理。

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Les, there are two major impacts in the quarter. The first one is we purposely decided not to sell additional volume in November. So November, obviously, was kind of a blank for Solta in China. Conversely, we start selling directly to the market in December. So that provided kind of a partial offset. And then on top of that, due to purchasing accounting, we basically had to step up on some of the volume that was sold to our customers in December.

    萊斯,本季有兩個主要影響因素。第一點是,我們特意決定11月不增加銷售量。所以很顯然,11 月對 Solta 在中國來說是一個空白期。相反,我們從12月開始直接向市場銷售。所以這就起到了一種部分補償作用。此外,由於採購會計方面的規定,我們不得不提高 12 月賣給客戶的數量。

  • Net-net, it's about a $10 million to $15 million hit from an EBITDA perspective in the quarter.

    總的來說,從 EBITDA 的角度來看,本季將損失約 1,000 萬至 1,500 萬美元。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Do you want to take the revenue gap on the Aplenzin LOE?

    你想承擔 Aplenzin LOE 的收入缺口嗎?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. Aplenzin, the way I would model it is kind of a standard erosion curve. We are expecting a number of competitors to come immediately after we lose exclusivity on Aplenzin, which is in June of this year. And so I would not expect any unusual behavior there.

    是的。Aplenzin,我建模的方式有點像是標準的侵蝕曲線。我們預計在今年 6 月失去 Aplenzin 的獨家經銷權後,將會有許多競爭對手立即湧入市場。因此,我預計那裡不會出現任何異常情況。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Les, you had a follow-up?

    萊斯,你還有後續問題嗎?

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Yeah. For Jonathan, perhaps on Larsucosterol, can you share some color around the Phase 3 study design? What effect size are you powering for? And what control mortality rate would you assume? And I guess, what's the delta in survival do you think that's sufficient for filing?

    是的。喬納森,或許關於 Larsucosterol,您能否分享一下 3 期研究設計方面的一些資訊?你們的目標效應量是多少?你認為對照組的死亡率會是多少?那麼,你認為生存率的提升幅度達到多少才足以提出申請呢?

  • Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

    Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

  • Yeah, it's a great question. So first of all, in terms of the design of the study, we've started the study now in record time, three months after we acquired the drug from DURECT. It will be a US-only study. It will include about 350 patients randomized between drug and placebo, and the primary endpoint is 90-day transplant-free survival.

    是的,這是一個很好的問題。首先,就研究設計而言,我們在創紀錄的時間內開始了這項研究,從 DURECT 獲得該藥物後僅三個月就啟動了這項研究。這項研究僅在美國進行。研究將納入約 350 名患者,隨機分為藥物組和安慰劑組,主要終點為 90 天無移植存活期。

  • We've had discussions with regulators, with the FDA about this and feel very confident about it. It's somewhat fairly similar to the design of the Phase 2 trial that DURECT ran. We've just made some design improvements, and we think the trial will be a bit more efficient than was run in Phase 2.

    我們已經與監管機構和美國食品藥物管理局(FDA)就此進行討論,對此我們非常有信心。它與 DURECT 進行的 2 期試驗的設計在某種程度上相當相似。我們剛剛進行了一些設計改進,我們認為這次試驗會比第二階段的試驗更有效率。

  • Now to your question about the effect size, I think we've followed the Phase 2 results, and we're data-driven and following what was seen in Phase 2. We designed the trial to reflect that. DURECT saw over 50% reduction in 90-day mortality. We believe that if we can replicate that, that would be an amazing result.

    現在回答你關於效應量的問題,我認為我們已經遵循了第二階段的結果,我們以數據為導向,並遵循第二階段觀察到的情況。我們設計的試驗方案就體現了這一點。DURECT 使 90 天死亡率降低了 50% 以上。我們相信,如果我們能夠複製這種效果,那將是一個驚人的結果。

  • To remind you, there's actually no therapies approved right now, no therapies available really for this patient population. So we think this would be a huge advancement in the management of these patients and will be really very important for us and for patients out there. Does that answer your question?

    再次提醒您,目前實際上沒有任何療法獲得批准,也沒有任何療法真正適用於這類患者群體。因此,我們認為這將是對這些患者的管理的一大進步,對我們和廣大患者來說都非常重要。這樣回答了你的問題嗎?

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Yes, very helpful.

    是的,很有幫助。

  • Operator

    Operator

  • Michael Freeman, Raymond James.

    Michael Freeman,Raymond James。

  • Michael Freeman - Analyst

    Michael Freeman - Analyst

  • My first is on Xifaxan. I wonder if -- it is fair to think that 2026 will be a peak year for Xifaxan sales given we have some renegotiated rates under Medicare for 2027? And if that holds true, what are your plans to accelerate sales during 2026 and mitigate the impact of the renegotiated rates under Medicare in '27?

    我的第一劑是利福昔明。我想知道——考慮到我們已經根據 Medicare 重新協商了 2027 年的費率,是否可以合理地認為 2026 年將是 Xifaxan 銷售的高峰年?如果情況屬實,您計劃在 2026 年加快銷售,並減輕 2027 年醫療保險重新談判費率的影響?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, Michael, thanks for the question. As you know, since I became the CEO, my focus has been on Xifaxan and driving growth. And that was the one thing that drove the decision to have our AI engine and build it. We think we have a best-in-class engine here, which has really helped our field forces be very efficient in terms of who they're speaking to and how frequently they're speaking and what they're actually delivering in the message of what the HCP wants.

    是的,邁克爾,謝謝你的提問。如你所知,自從我擔任執行長以來,我的工作重點一直放在 Xifaxan 和推動其成長上。正是這一點促使我們決定開發並建構自己的人工智慧引擎。我們認為我們擁有業內最佳的引擎,這確實幫助我們的第一線人員在與誰溝通、溝通頻率以及實際傳達 HCP 想要的訊息方面都提高了效率。

  • So the focus here has been continuing to accelerate. As you saw, we continue to grow Xifaxan. We're already on the market over 20 years. We still delivered a 10% net sales growth in Q4. So as we look to '26, we will continue to stay focused on driving execution in the channels where we compete.

    因此,這裡的重點一直是繼續加速發展。正如你所看到的,我們持續發展 Xifaxan。我們已經在市場上經營了20多年。第四季我們仍然實現了10%的淨銷售額成長。展望 2026 年,我們將繼續專注於在我們所競爭的管道中推動執行。

  • So we feel confident in being able to continue to grow in those channels. There's still a lot of unmet need for patients to be treated with OHE. As I've said on previous calls, right now, we're probably still only treating. Of course, this is patients that are diagnosed, probably 40% to 50%. So there's still a good amount of space there to continue to grow before the product goes LOE.

    因此,我們有信心在這些管道繼續發展壯大。目前仍有許多患者對 OHE 治療有未滿足的需求。正如我之前在電話會議中所說,目前我們可能仍然只是在進行治療。當然,這指的是已確診的患者,大概佔 40% 到 50%。所以,在產品停產之前,還有很大的成長空間。

  • I want to -- maybe JJ wants to add something to that?

    我想——或許JJ想補充一些內容?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. Michael, a couple of things just to highlight. While we'll continue to grow the business in the channels we're currently selling Xifaxan, which exclude the Medicaid and, to a certain extent, the 340B channel. On a reported basis, 2025 might be the peak year for Xifaxan just because we had some onetime benefits in the year. that will not repeat in 2026. I think we've clarified that in the prepared remarks.

    是的。邁克爾,有幾點需要特別說明。我們將繼續拓展目前銷售 Xifaxan 的通路業務,但不包括 Medicaid 管道,並且在某種程度上也不包括 340B 通路。據報道,2025年可能是利福昔明(Xifaxan)的銷售巔峰之年,因為那一年我們獲得了一些一次性的收益,而這些收益在2026年不會再出現。我認為我們在準備好的發言稿中已經闡明了這一點。

  • So I'll mention a couple of elements. First, at the end of the third quarter, we had to adjust our gross to net percentage to reflect the fact that we had exited Medicaid. So that was kind of a good guy in the third quarter. In the fourth quarter, we still had some residual volume from Medicaid states that were not discounted by definition because we had exited programs. So that provided also another benefit.

    所以我提一下幾個要點。首先,在第三季末,我們不得不調整毛利與淨利的比率,以反映我們已經退出醫療補助計劃的事實。所以他在第三節表現還不錯。第四季度,我們仍然有一些來自醫療補助州的剩餘業務量,由於我們已經退出了這些項目,因此這些業務量並未按定義進行折扣。所以這也帶來了另一個好處。

  • And then conversely, if you look at 2026, there will need to be an adjustment of our gross to net accrual in the fourth quarter of 2026 to reflect the fact that the new CMS rebate will become effective on January 1, 2027. So a lot of accounting pluses and minuses, but I think you're thinking about the right way, which is operationally in the channels we currently serve. We'll continue to grow our Xifaxan revenue in '26.

    反過來,如果你看看 2026 年,那麼我們需要在 2026 年第四季度調整毛應計額到淨應計額,以反映新的 CMS 退款將於 2027 年 1 月 1 日生效的事實。所以會計方面有很多利弊,但我認為你的思考方式是正確的,那就是在我們目前服務的管道中運作。2026年,我們將繼續提高Xifaxan的收入。

  • Michael Freeman - Analyst

    Michael Freeman - Analyst

  • Okay. Okay. And now a follow-up. I guess, thinking another way about, I guess, the timing and your framework for thinking about the full separation of Bausch + Lomb. What are you hoping to see develop within that business before it's appropriate to pursue the full separation?

    好的。好的。現在來個後續。我想,換個角度思考一下,我想,關於時機以及你思考博士倫完全分離的框架。您希望看到該業務在適當的時候發展到什麼程度,才會考慮全面分離?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, Michael, I think when we look at it, right, as we talked about in the prepared remarks, the refinancing provided great flexibility for us. So it was a significant achievement this year. And I don't know if you had a chance to listen to Bausch + Lomb's call this morning.

    是的,邁克爾,我認為當我們審視這個問題時,正如我們在準備好的演講稿中所談到的,再融資為我們提供了巨大的靈活性。所以這是今年取得的重大成就。我不知道你今天早上有沒有機會聽博士倫的電話會議。

  • So I think, I look at it this way. We believe in the Bausch + Lomb plan, the growth story, the margin expansion story, and the selling and operational excellence. They have a robust pipeline. They have a robust product portfolio today. And then if you had listened to Investor Day, where their pipeline is going. So we really believe in that pipeline.

    所以我覺得,我是這麼看的。我們相信博士倫的計劃、成長故事、利潤率擴張故事以及卓越的銷售和營運能力。他們擁有強大的產品線。他們目前擁有強大的產品組合。如果你聽了投資者日的講話,就會知道他們的產品線正在向何方發展。所以我們對這人才培養管道非常有信心。

  • And then lastly, they have a great team, and they had a great quarter, and we are really excited about the future of Bausch + Lomb and given the fact that we own 88% of it. So we're just looking now to the market to reflect the value in Bausch + Lomb.

    最後,他們擁有一支優秀的團隊,而且本季業績出色,鑑於我們擁有博士倫 88% 的股份,我們對博士倫的未來感到非常興奮。所以我們現在正關注市場,以反映博士倫的價值。

  • JJ, do you have any further comments?

    JJ,你還有其他要補充的嗎?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • No, the only thing I would just clarify or add is that the refinancing basically, based on our projections, allow us to pretty much deal with the maturities until the end of 2028, assuming we maintain exclusivity on Xifaxan until January 1, 2028. So that flexibility allows us to really be patient and to wait for really the share price of B&L to reflect the improved execution and the financials that have been shared with investors late last year during Investor Day. So that's point number one.

    不,我唯一要澄清或補充的是,根據我們的預測,此次再融資基本上使我們能夠應對到 2028 年底的到期債務,前提是我們保持 Xifaxan 的獨家銷售權到 2028 年 1 月 1 日。這種靈活性使我們能夠真正保持耐心,等待 B&L 的股價真正反映出去年底投資者日上與投資者分享的改進的執行情況和財務數據。這是第一點。

  • Point number two is, in light of what I think we've discussed last year, the separation per se will have to be in the form of really selling our B&L equity stake. There's been, I think, in the past, some chatter around some distribution of B&L shares, but I think the highest probability outcome will be in the form of selling down our equity stake.

    第二點是,鑑於我認為我們去年討論過的內容,分離本身必須以真正出售我們在 B&L 的股權的形式進行。我認為,過去曾有一些關於B&L股份分配的傳聞,但我認為最有可能的結果是減持我們的股權。

  • Operator

    Operator

  • Glen Santangelo, Barclays.

    Glen Santangelo,巴克萊銀行。

  • Glen Santangelo - Equity Analyst

    Glen Santangelo - Equity Analyst

  • Tom, I think everybody just generally accepts the fact that the near-term results, they continue to look fantastic. But sort of based on our incoming call volume, it seems like everybody just wants to talk about the EBITDA impact in '27 coming from the IRA and the pricing changes and then again, in sort of 2028 with the LOE. And I seem to remember, I thought you gave us some guidance in the past about how '27 EBITDA may shape up relative to '25.

    湯姆,我認為大家普遍認同的是,短期結果看起來還是很棒。但根據我們接到的電話數量來看,似乎每個人都只想談論 2027 年 IRA 和定價變化對 EBITDA 的影響,以及 2028 年 LOE 的影響。我好像記得,您之前曾就 2027 年的 EBITDA 與 2025 年相比可能的情況給予我們一些指導。

  • And I couldn't remember specifically, but I don't know if there's anything you can give us to give us a better sense of the EBITDA trajectory just sort of given those two events that are kind of coming up.

    我記不太清了,但我不知道您是否能提供一些信息,讓我們更好地了解即將到來的這兩個事件對 EBITDA 走勢的影響。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Glen, thanks for the question. And yes, the results, we're really pleased with the 2025 results. I'm going to hand it over to JJ because on previous calls, he's discussed this.

    格倫,謝謝你的提問。是的,我們對2025年的結果非常滿意。我打算把這件事交給 JJ,因為他之前在電話裡討論過這個問題。

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Glen, what we've said in prior calls, actually more specifically in Q3 is that the average of 2026 and 2027 would be fairly similar to the EBITDA that we deliver in 2025. And despite the overperformance that we've had in 2025 and the very strong fourth quarter, I can reiterate that guidance.

    Glen,我們在先前的電話會議中已經說過,尤其是在第三季度,2026 年和 2027 年的平均值將與我們在 2025 年實現的 EBITDA 相當接近。儘管我們在 2025 年取得了超乎預期的業績,並且第四季度表現非常強勁,但我可以重申這一預期。

  • Now obviously, given that we've provided guidance for 2026, you can figure it out exactly how we're thinking about 2027 in light of that guidance. But yes, there are obviously partial offset to that higher CMS discount that provide us to soften, I would say, the relative drop that you can see, but we've got other growth platforms that we continue to work on, starting with Solta and some of the other segments. So I think that will help you rationalize the implied number for 2027.

    顯然,鑑於我們已經提供了 2026 年的指導意見,您可以根據這些指導方針來推斷我們是如何考慮 2027 年的。但確實,較高的 CMS 折扣顯然可以部分抵消,從而緩解您看到的相對跌幅,但我們還有其他成長平台正在繼續努力,首先是 Solta 和其他一些細分市場。所以我認為這將有助於你合理化 2027 年的隱含數字。

  • Glen Santangelo - Equity Analyst

    Glen Santangelo - Equity Analyst

  • All right. Maybe if I could just ask one quick follow-up on the cap structure. Obviously, you made a lot of good progress here. And Tom, I don't want to put words in your mouth, but it sounds like you believe that you're at a place where you can start doing business development currently, and you've done that this quarter. But just to sort of follow up on JJ's comments, you now believe the plan will ultimately be to sell Bausch + Lomb as opposed to do the spin.

    好的。或許我可以再問一個關於資本結構的問題。顯然,你在這裡取得了很大的進步。湯姆,我不想替你說話,但聽起來你認為你現在已經到了可以開始進行業務拓展的階段,而且你這季度也確實做到了。但為了進一步回應 JJ 的評論,你現在認為最終的計劃是出售博士倫,而不是進行粉飾。

  • Does this -- would the sale have to be an all-in one shot? Or could it theoretically you sell different pieces of the company or different percentages of the company down as need be to handle the upcoming maturities, which seemingly are not until 2028 anyway. So it seems like you have some time. So I just wanted to really try to understand the strategy of how you may approach Bausch + Lomb just sort of given you have a little bit of time on your side versus maybe near-term business development priorities. I'll stop there.

    也就是說,這筆交易必須一次全部完成嗎?或者理論上,你可以根據需要出售公司不同的股份或不同比例的股份來應對即將到期的債務,而這些債務似乎要到 2028 年才會到期。看來你還有一些時間。所以,我只是想真正了解一下,鑑於您有一些時間可以支配,而不是著眼於近期業務發展重點,您會如何制定與博士倫的合作策略。我就說到這裡吧。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thanks, Glenn. So when it comes to business development, of course, doing the refinancing, the finance team and the legal team did an outstanding job. This is just incredible what we've been able to do and to give us runway. And so with that runway, and we're able to now really do focusing on BD, as you saw with the direct acquisition that we did in the third quarter, the Shibo acquisition in the fourth quarter and looking at our capital allocation and where we can create the best value.

    謝謝你,格倫。所以,在業務發展方面,當然包括再融資方面,財務團隊和法律團隊都做得非常出色。我們所取得的成就以及給予我們的發展空間,簡直令人難以置信。因此,有了這筆資金,我們現在能夠真正專注於業務拓展,正如你們在第三季度看到的直接收購,以及第四季度對 Shibo 的收購,並審視我們的資本配置以及我們可以在哪裡創造最大價值。

  • And there is a lot of assets out there that we continue to screen and looking for the right fit for Bausch Health. As I said in a previous question, one of the greatest assets we have is our commercial team and our commercial capabilities in worldwide. So that is going to be the focus going forward, of course, all driven by being able to do the refinancing.

    我們仍在不斷篩選和尋找適合博士倫健康的優質資產。正如我在先前的問題中所說,我們最大的資產之一就是我們的商業團隊和我們在全球範圍內的商業能力。所以,這當然將是未來的重點,一切都取決於能否再融資。

  • I'll hand it off to JJ to add more to your question.

    我會把這個問題交給JJ,讓他補充更多內容。

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. So when it comes to the monetization of our B&L equity stake, really all options are on the table. I think what will guide really our monetization decisions, as we said in our prepared remarks, is really shareholder value creation. The flexibility that we've got and the extended runway that we've created through the refinancing of $9.6 billion of our debt last year now allows us to be more patient and to evaluate all possible options to monetize our equity stake while at the same time, creating shareholder value.

    是的。所以,就我們所持有的 B&L 股權的變現而言,所有方案都在考慮範圍內。我認為,正如我們在準備好的演講稿中所說,真正指導我們貨幣化決策的,是創造股東價值。去年,我們透過對 96 億美元的債務進行再融資,獲得了更大的靈活性和更長的資金周轉期,這使我們能夠更有耐心,評估所有可能的股權變現方案,同時創造股東價值。

  • So that's the way we think about it.

    這就是我們的想法。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • And I think, Glen, as we look at the performance for 2025, the focus is going to be getting more products into the hands of our commercial team. So it's going to be a focus now continuing to look for assets to bring into the portfolio, not only that are possibly already on the market, but the fact of what we can do from a development perspective in R&D.

    格倫,我認為,展望 2025 年的業績,重點將是讓我們的商業團隊獲得更多產品。因此,接下來的重點將繼續尋找可以納入投資組合的資產,不僅包括可能已經在市場上的資產,還包括我們在研發方面可以從開發角度所做的事情。

  • Operator

    Operator

  • Jason Gerberry, Bank of America.

    傑森‧格伯里,美國銀行。

  • Chi Fong - Analyst

    Chi Fong - Analyst

  • This is Chi on for Jason. One and another follow-up. So the first one is, you mentioned there were some higher-than-planned residual volume from several state Medicaid. Can you quantify the impact to 4Q? And was that impact segment across portfolio? If not, which product benefit the most from this onetime dynamic?

    這是 Chi 為 Jason 主持的節目。一個後續。首先,您提到一些州的醫療補助計劃出現了高於計劃的剩餘量。你能量化對第四季的影響嗎?這種影響是否波及整個投資組合?如果不是,那麼哪款產品最能從這種一次性的市場動態中受益?

  • And my follow-up is on the scope of BD. How large of a BD are you willing to consider based on your current capital structure?

    我的後續問題是BD的範圍。根據您目前的資本結構,您願意考慮多大的經紀業務規模?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, Chi, thanks for the question. I'll take your second question first, and then I'll hand it off to JJ. We're looking at all types. As you know, we are constrained in terms of the capital structure that we have and what we can -- how much we can spend.

    是的,Chi,謝謝你的提問。我先回答你的第二個問題,然後再交給 JJ。我們正在研究所有類型。如您所知,我們的資本結構和我們能花的錢(也就是我們能花多少錢)都受到限制。

  • But there is -- as we look at it, we look at our portfolio and how do we -- are we able to maximize it? And is there assets that we could bring in at a certain value? Are there other assets that some others could be interested in? So we look at it -- we keep a very open approach to type of deals we can do and the size of the deal we can do. And so that's the framework that we're using today.

    但是,當我們審視我們的投資組合時,我們該如何——我們能否最大化其收益?我們能否以一定價值引進某些資產?還有其他一些人可能感興趣的資產嗎?所以我們對此持非常開放的態度,無論交易類型和交易規模如何。這就是我們今天所使用的框架。

  • I'll hand it over to JJ on your question on the residual volume on Xifaxan.

    關於您提出的關於利福昔明殘餘體積的問題,我將交給 JJ 來回答。

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. Most of that volume is really associated with Xifaxan in the fourth quarter and that really happened in October, November. It was less than $50 million in terms of revenue.

    是的。大部分銷售實際上與第四季度的利福昔明(Xifaxan)有關,而這主要發生在 10 月和 11 月。營收不到5000萬美元。

  • Operator

    Operator

  • Michael Nedelcovych, TD Cowen.

    邁克爾·內德爾科維奇,TD·考恩。

  • Michael Nedelcovych - Analyst

    Michael Nedelcovych - Analyst

  • I have two. My first is on the outlook for Xifaxan generics. What are the key events that we should be watching that could decide if a Xifaxan generic becomes available before 2028? We're less than two years away now. So I'm curious what would you say is your level of confidence that Xifaxan will retain exclusivity through to the settlements with generics companies in 2028? That's my first question.

    我有兩個。我的第一個問題是利福昔明仿製藥的前景。哪些關鍵事件可能決定利福昔明仿製藥能否在 2028 年前上市?我們應該關注這些關鍵事件嗎?距離現在不到兩年了。所以我很好奇,您對利福昔明(Xifaxan)在2028年與仿製藥公司達成和解之前保持獨家銷售權有多大信心?這是我的第一個問題。

  • And then my second question is more of a follow-up. It relates to the medium-term outlook. JJ, you hinted at this in a previous response, but I think you said on the last call that EBITDA averaged across 2026 and 2027 would be roughly flat versus 2025. So we now know that you're looking for low- to mid-single-digit EBITDA growth this year. Should we then assume a step down in 2027 of a similar magnitude?

    我的第二個問題更像是後續問題。它與中期前景有關。JJ,你在之前的回覆中暗示過這一點,但我認為你在上次電話會議上說過,2026 年和 2027 年的 EBITDA 平均值將與 2025 年大致持平。所以我們現在知道,您今年的目標是實現個位數低至中等的 EBITDA 成長。那麼我們是否應該假設 2027 年會出現類似幅度的下降?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, Mike, I'll take the first question, and I'll let JJ take the second. As you know, we know we will have a generic in January 1, 2028. So as we look at it, we're trying to maximize the value of Xifaxan today. As you also know from the public records, Teva continues to be the first filer as first filer status. There's two cases right now in the DC District Court on appeal. And that's taking its course.

    好的,麥克,第一個問題我來回答,第二個問題讓JJ來回答。如您所知,我們知道我們將在 2028 年 1 月 1 日推出仿製藥。因此,從目前的角度來看,我們正在努力最大化 Xifaxan 的價值。正如您從公開記錄中了解到的,梯瓦製藥仍然是第一個提交申請的公司,並保持第一個提交申請公司的地位。目前華盛頓特區地方法院正在審理兩起上訴案件。事情正在按部就班地發展。

  • And then lastly, we have our other patent case in the New Jersey District Court on the new patents at issue with Amneal and Norwich, of which we're still waiting to see, but is there -- the 30-month stay applies to Norwich second ANDA and still needs to be determined, which we believe the 30-month stay applies. Basically, the way we look at it is we'll continue to provide updates on these matters as it moves through the court system.

    最後,我們在新澤西州地方法院還有一起與Amneal和Norwich有關的專利案件,涉及新專利,我們仍在等待結果,但30個月的暫緩執行適用於Norwich的第二個ANDA,但仍需確定,我們認為30個月的暫緩執行適用於該ANDA。基本上,我們的做法是,我們會隨著案件在法院系統的進展,繼續提供最新資訊。

  • JJ?

    JJ?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. So you're correct. There will be a dip in 2027. I think the math basically suggests that 2027 would be around $2.7 billion, if you follow the math and the logic that I just outlined.

    是的。你說得對。2027年將會下滑。我認為,如果按照我剛才概述的計算和邏輯,2027 年的計算結果應該在 27 億美元左右。

  • Operator

    Operator

  • We have reached the end of our question-and-answer session. I'd like to turn the floor back over to Tom Appio, CEO, for closing remarks.

    我們的問答環節到此結束。現在我把發言權交還給執行長湯姆·阿皮奧,請他作總結發言。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Well, thank you all for joining us today for your questions. We closed out another solid quarter and a year of meaningful growth, supported by results across a broad portfolio. Our progress in 2025 reinforces the foundation we are carrying into 2026 and positions us to deliver another year of strong execution and continued progress.

    謝謝各位今天參加我們的節目並提出問題。我們又順利結束了一個穩健的季度和一年的顯著成長,這得益於我們廣泛的業務組合所取得的業績。我們在 2025 年取得的進展鞏固了我們進入 2026 年的基礎,並使我們能夠在新的一年中繼續保持強勁的執行力和持續的進步。

  • I thank you again for the time and the interest you have in our company, and enjoy the rest of your evening.

    再次感謝您抽出時間並對我們公司表現出興趣,祝您晚安。

  • Operator

    Operator

  • Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.

    謝謝。今天的電話會議和網路直播到此結束。現在您可以斷開線路了,祝您有美好的一天。感謝您今天的參與。